A Phase III Study of Ceralasertib plus Durvalumab versus Docetaxel inPatients with Non-Small Cell Lung Cancer Whose Disease Progressed On or After PriorAnti-PD-(L)1 Therapy And Platinum-Based Chemotherapy

AstraZeneca AB0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年7月25日

试验速览

暂无简介。

•1.Participant must be greater than or equal to 18 years at the time of screening
•2.Histologically or cytologically documented NSCLC that is locally advanced or metastatic according to Version 8 of the IASLC Staging Manual in Thoracic Oncology.
•3.Documented epidermal growth receptor factor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type status as determined at a local laboratory.
•4.Documented radiological PD whilst on or after receiving the most recent treatment regimen.
•5.Eligible for second- or third-line therapy and must have received an anti-PD-(L)1 therapy and a platinum doublet containing therapy for locally advanced or metastatic NSCLC either separately or in combination.
•6.Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status of 0 or 1.
•7.Adequate organ function and marrow reserve Minimum life expectancy of 12 weeks.
•8.Body weight greater than 30 kg and no cancer-associated cachexia.
•9.Negative pregnancy test (serum test) for women of childbearing potential (WOCBP).

•1.Participant with mixed SCLC and NSCLC histology.
•2.History of another primary malignancy except for malignancy treated with curative intent with no known active disease greater than or equal to 5 years before the first dose of study intervention.
•3.Persistent toxicities (CTCAE Grade greater than 2) caused by previous anticancer therapy.
•4.Active or prior documented autoimmune or inflammatory disorders.
•5.Participants who have received more than one line of prior anti-PD-(L)1, either alone or in any combination.
•6.Participants-
•a.Must not have experienced a toxicity that led to permanent discontinuation of the prior anti-PD(L)1 therapy.
•b.All AEs while receiving prior anti-PD(L)1 therapy must have completely resolved.
•c.Must not have experienced a Grade greater than or equal to 3 immune-mediated adverse event (imAE) or an immune-related neurologic or ocular AE of any grade while receiving prior anti-PD(L)1 therapy.
•d.Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of greater than 10 mg prednisone or equivalent per day.
•7.Participants who have received more than one prior line of platinum-based chemotherapy in metastatic setting.
•8.Participants who have received a prior ataxia telangiectasia and Rad3-related protein (ATR) inhibitor.

发起方